OVERVIEW

Tenosynovial Giant Cell Tumor Diagnosis and Systemic Therapy: Interprofessional Strategies for Enhanced Outcomes is organized by i3 Health.

Dates Available:
July 14, 2026 - July 13, 2027

Statement of Need:
Tenosynovial giant cell tumor (TGCT) is a rare, locally aggressive neoplasm of the synovium, bursae, and tendon sheaths that can lead to chronic pain, recurrent joint swelling, progressive functional impairment, and irreversible joint destruction. Localized TGCT can often be effectively managed with surgical excision; however, diffuse TGCT is associated with a substantial risk of recurrence after surgery. Recent advances have led to the approval of systemic therapies targeting the CSF-1/CSF1R signaling pathway for patients with symptomatic TGCT that is not amenable to surgery. These CSF1R inhibitors have demonstrated meaningful improvements in tumor response, range of motion, physical function, and patient-reported outcomes. To individualize treatment decisions in a rapidly changing therapeutic landscape, clinicians must navigate important differences in toxicity profiles and monitoring requirements to optimize long-term outcomes (Stacchiotti et al, 2023; Assi et al, 2025). In this Virtual Tumor Board activity, Brian E. Brigman, MD, PhD; Jason L. Hornick, MD, PhD; Robert A. Lefkowitz, MD; and Richard F. Riedel, MD, explore interprofessional strategies to equip the multidisciplinary team to accurately diagnose localized and diffuse TGCT, integrate evolving consensus recommendations, and individualize treatment decisions for enhanced outcomes in TGCT.

Learning Objectives:
Upon completion of this activity, participants should be able to

Identify clinical, pathologic, and radiologic features of localized and diffuse TGCT to support a timely and accurate diagnosis
Apply current evidence and expert guidance to select appropriate treatment strategies for patients with TGCT
Implement risk mitigation and monitoring strategies to reduce complications associated with systemic therapies for TGCT
Recognize and manage common and serious CSF1R inhibitor–related adverse events

ACCREDITATION & CREDITS

Jointly Accredited Provider:

In support of improving patient care, i3 Health is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

PHYSICIANS
i3 Health designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.25 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

By providing this information, participants are agreeing to allow i3 Health to share this information with the ACCME.

Physician Assistants
i3 Health has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.25 AAPA Category 1 CME credits. Approval is valid until 7/13/27. PAs should only claim credit commensurate with the extent of their participation.

Nurse Practitioners
The American Academy of Nurse Practitioners Certification Program (AANPCP) accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME. Individuals are responsible for checking with the AANPCP for further guidelines.

1.25 AMA PRA Category 1 Credits™

1.25 MOC

1.25 AAPA

FACULTY

Richard Riedel

MDMedical Oncology, Internal Medicine

Jason L. Hornick

MD, PhDPathology, Anatomic Pathology

Brian Brigman

MD, PhDOrthopedic Surgery

Robert Lefkowitz

MDRadiology, Diagnostic Radiology

TARGET AUDIENCE

PhysicianPhysician AssistantRadiologistsHealthcare ProvidersPathologistsNurse PractitionersMedical OncologistsAdvanced Practice ProvidersOrthopedic Oncologists

SPECIALITIES

OncologyPathologyRadiologyOrthopedics

TERMS & CONDITIONS

DISCLOSURE OF RELEVANT FINANCIAL INFORMATION WITH INELIGIBLE COMPANIES
i3 Health endorses the standards of the ACCME that require everyone in a position to control the content of a CME activity to disclose all financial relationships with ineligible companies that are related to the content of the CME activity. CME activities must be balanced, independent of commercial bias, and promote improvements or quality in health care. All recommendations involving clinical medicine must be based on evidence accepted within the medical profession.

A conflict of interest is created when an individual has an opportunity to affect CME content about products or services of an ineligible company with which he/she has a financial relationship, which therefore may bias their opinions and teaching. This may include receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, stocks, or other financial benefits.

i3 Health will identify, review, and mitigate all relevant financial relationships that speakers, authors, or planners disclose prior to an educational activity being delivered to learners. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation. i3 Health does not endorse any products or services.

Relevant financial relationships exist between the following individuals and ineligible companies:Relevant financial relationships exist between the following individuals and ineligible companies:

The i3 Health planners, reviewers, and managers have nothing to disclose.

Brian E. Brigman, MD, PhD, discloses that he has served on an advisory board or panel for Daiichi Sankyo, Deciphera, and Musculoskeletal Transplant Foundation; and that he has received grants/research support from Musculoskeletal Transplant Foundation.

Jason L. Hornick, MD, PhD, has no relevant financial relationships to disclose.

Robert Lefkowitz, MD, has no relevant financial relationships to disclose.

Richard F. Riedel, MD, discloses that he has served on an advisory board or panel for AADi, Adaptimmune, Bayer, Blueprint, Boehringer Ingelheim, Cogent, Daiichi Sankyo, Deciphera, EMD Serono, GlaxoSmithKline, Ipsen, NanoCarrier, Recordati, Replimmune, and SpringWorks; that he has served as a consultant for GlaxoSmithKline and SpringWorks; and that he has received grants/research support from AADi, Adaptimmune, AROG, Ayala, BioAtla, Blueprint, Cogent, Daiichi Sankyo, Deciphera, GlaxoSmithKline, InhibRx, Intensity Therapeutics, Kura Oncology, NanoCarrier, Oncternal, PTC Therapeutics, SARC, Servier, SpringWorks, SynOx Therapeutics, Tracon, Trillium, and US WorldMeds.

i3 Health has mitigated all relevant financial relationships.

INSTRUCTIONS TO RECEIVE CREDIT
In order to receive credit for this activity, participants must attend the scheduled activity and submit a completed evaluation at the end of the activity.

COMMERCIAL SUPPORT
Supported by an independent educational grant from Daiichi Sankyo.

CONTACT INFORMATION
Technical queries or questions regarding activity credit should be directed to i3 Health at support@emedevents.com.

DISCLAIMER

The information provided at this CME activity is for continuing education purposes only and is not meant to substitute for the independent medical/clinical judgment of a health care provider relative to diagnostic and treatment options of a specific patient’s medical condition.